Healthcare provider profile · identity verified

Tiffany Cesca, APRN

Nurse Practitioner · AVON, CT · NPI 1568075539

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	196	63
Amlodipine Besylate	Amlodipine Besylate	144	46
Lisinopril	Lisinopril	135	53
Levothyroxine Sodium	Levothyroxine Sodium	117	40
Pantoprazole Sodium	Pantoprazole Sodium	115	44
Rosuvastatin Calcium	Rosuvastatin Calcium	113	46
Gabapentin	Gabapentin	100	29
Albuterol Sulfate Hfa	Albuterol Sulfate	94	36
Metformin Hcl	Metformin Hcl	88	37
Montelukast Sodium	Montelukast Sodium	77	22
Furosemide	Furosemide	70	18
Losartan Potassium	Losartan Potassium	55	21
Hydrochlorothiazide	Hydrochlorothiazide	49	17
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	49	11
Omeprazole	Omeprazole	48	17
Ozempic	Semaglutide	48	suppressed
Fluticasone Propionate	Fluticasone Propionate	45	15
Trazodone Hcl	Trazodone Hcl	45	12
Lorazepam	Lorazepam	42	13
Meloxicam	Meloxicam	41	15
Escitalopram Oxalate	Escitalopram Oxalate	37	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	37	13
Pravastatin Sodium	Pravastatin Sodium	37	15
Prednisone	Prednisone	36	25
Carvedilol	Carvedilol	35	suppressed
Clonidine Hcl	Clonidine Hcl	35	11
Metoprolol Succinate	Metoprolol Succinate	34	suppressed
Simvastatin	Simvastatin	34	13
Tramadol Hcl	Tramadol Hcl	33	suppressed
Alprazolam	Alprazolam	31	suppressed
Famotidine	Famotidine	30	12
Ibuprofen	Ibuprofen	30	14
Alendronate Sodium	Alendronate Sodium	29	suppressed
Duloxetine Hcl	Duloxetine Hcl	28	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	27	suppressed
Pregabalin	Pregabalin	27	suppressed
Clopidogrel	Clopidogrel Bisulfate	26	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	24	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	24	12
Naproxen	Naproxen	23	suppressed
Diclofenac Sodium	Diclofenac Sodium	22	suppressed
Carisoprodol	Carisoprodol	21	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	21	suppressed
Potassium Chloride	Potassium Chloride	21	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	20	suppressed
Celecoxib	Celecoxib	19	suppressed
Januvia	Sitagliptin Phosphate	19	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	19	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	19	suppressed
Ezetimibe	Ezetimibe	18	suppressed
Oxycodone Hcl	Oxycodone Hcl	18	suppressed
Sertraline Hcl	Sertraline Hcl	18	suppressed
Tradjenta	Linagliptin	18	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	17	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	16	11
Baclofen	Baclofen	16	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Clonazepam	Clonazepam	16	suppressed
Metformin Hcl Er	Metformin Hcl	16	suppressed
Methocarbamol	Methocarbamol	16	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	16	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	15	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	15	suppressed
Hydralazine Hcl	Hydralazine Hcl	14	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Allopurinol	Allopurinol	13	suppressed
Nystatin	Nystatin	13	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	13	suppressed
Trulicity	Dulaglutide	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	12	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	12	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	12	suppressed
Mounjaro	Tirzepatide	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	11
Tolterodine Tartrate Er	Tolterodine Tartrate	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Fluconazole	Fluconazole	11	suppressed
Latanoprost	Latanoprost	11	suppressed
Lidocaine	Lidocaine	11	suppressed
Primidone	Primidone	11	suppressed
Valsartan	Valsartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error